ENSC Ensysce Biosciences, Inc. Quarterly EPS earnings growth

Graphic logo of Ensysce Biosciences Inc. (ENSC)

Ensysce Biosciences (ENSC) relies on a narrow portfolio of drugs for opioid addiction, which creates high risks. Meanwhile, robotic systems and AI are accelerating the search for safe analgesics. Quarterly EPS progress helps assess the real efficiency of these investments, where 74.50 represents the latest metric reading. However, geopolitical tensions and sanctions are currently hindering global clinical trials of these innovations.

Ensysce Biosciences, Inc. (ENSC) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/11/2026

Analytical breakdowns for Ensysce Biosciences

- market value and analyst target forecast:
Price Chart ensysce.com|ENSC - Consensus Target
- market capitalization data:
Market Capitalization Ensysce|ENSC - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Ensysce Biosciences|ENSC - Accounting Capitalization|Market Value to Book Value Ratio ensysce.com|ENSC - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Equity Ratio Ensysce Biosciences|ENSC - Long-Term Liabilities to Capital|Short-Term Debt to Equity ensysce.com|ENSC - Company Total Debt Obligations|Debts to Book Capitalization Ensysce|ENSC - Company Long-Term Liabilities|Company Short-Term Debts Ensysce Biosciences|Quick Liquidity Indicator ensysce.com
- earnings and market multiples details:
ENSC - Final Profit|Projected Future Earnings Ensysce Biosciences|ENSC - Price to Earnings Ratio|Forward P/E Multiple ensysce.com|ENSC - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ensysce|ENSC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Ensysce Biosciences|ENSC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth ensysce.com|ENSC - Net earnings per share growth this year|Earnings growth forecast for next year Ensysce Biosciences
Analysis of all company metrics:Ensysce Biosciences Inc. - ENSC
Finished products of ensysce.com

For an investor in Ensysce Biosciences (ENSC), this metric serves as a marker for the efficiency of capitalizing costs associated with launching abuse-deterrent analgesics under full production capacity. The growth rate of quarterly earnings per share is calculated as the percentage change in net income per common share, confirming the fundamental stability of the business through objective cash returns.

Main competitors

Indivior (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Collegium Pharma|CRON (Cronos) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Canopy Growth Corp. CGC|Year-over-year earnings per share growth for the last twelve months High Tide Inc. (HITI)|auroramj.com - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Achieve Life Sciences, Inc. ACHV|Year-over-year net earnings per share change for the last twelve months skyebioscience.com (SKYE)|ANEB: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months InterCure Ltd.|nutriband.com (NTRB) - Year-over-year earnings per share growth for the last twelve months|NSRX - Year-over-year net earnings per share change for the last twelve months|IGC (India Globalization Capital) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months MIRA Pharma (MIRA)|Quarterly EPS earnings growth FLGC|IMCC - Earnings per share growth in annualized terms for the last twelve months|Adial Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ARTL|Titan Pharma - Quarterly EPS earnings growth|GNLN: Year-over-year earnings per share growth for the last twelve months|INM: Quarterly EPS earnings growth|AKAN - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Enveric Biosciences|Earnings per share growth in annualized terms for the last twelve months Bright Green Corp BGXX|Year-over-year earnings per share growth for the last twelve months Hempacco (HPCO)